Biosimilars in paediatric inflammatory bowel disease

Table 1 Treatment of Crohn’s disease paediatric patients with biosimilar infliximab

Study	Numberof patients	PCDAIbefore treatment	Time of assessmentafter induction	Remission(%)
Richmond et al[21]	29	27.5 (7.5-55)	12 wk	67
Chanchlani et al[19]	29	28 (20, 40)	3 mo	79
Sieczkowska-Golub et al[20]	36	52.5	14 wk	67

PCDAI: Paediatric Crohn's Disease Activity Index.

Table 2 Switching experiences among paediatric inflammatory bowel disease patients

Study	Number of patients	Time of follow up	Remission (%)
Kang et al[25]	32 CD and 6 UC	1 yr	78.9
Sieczkowska et al[24]	32 CD and 7 UC	8 ± 2.6 mo (range 2-11) for CD	88
		5 ± 3.6 mo (range 0-9) for UC	57

CD: Crohn’s disease; UC: Ulcerative colitis.

Table 3 Biosimilars approved by the European Medicinal Agency in use among inflammatory bowel disease patients[38-40]

Name of biosimilar	Manufacturer	Date of approval
Infliximab
Flixabi	Samsung Bioepis	May-16
Inflextra	Hospira	Sep-13
Remsima	Celtrion	Sep-13
Adalimumab
Amgevita	Amgen	Jan-17
Cyltezo	Boehringer Ingelheim	Sep-17
Hyrimoz	Sandoz	Jun-18
Imraldi	Samsung Bioepis	June 20016
Solymbic	Amgen	Jan-17

Table 4 Biosimilars approved by the Food and Drug Administration in use among inflammatory bowel disease patients[41]

Name	Brand name	Date of licensure
Infliximab
Infliximab-abda	Renflexis	Apr-17
Infliximab-dyyb	Inflectra	Apr-16
Infliximab-qbtx	Ixifi	Dec-17
Adalimumab
Adalimumab-adbm	Cyltezo	Aug-17
Adalimumab-atto	Amjevita	Sep-16